

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Palynziq™ Clinical Edit
<b>First Implementation Date:</b>	April 18, 2019
<b>Proposed Date:</b>	June 18, 2020
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of Palynziq™ (pegvaliase-pqpz)

**Why Issue Selected:** Palynziq™ (pegvaliase-pqpz) is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management. PKU results from a deficiency of phenylalanine hydroxylase, leading to elevated blood and urine concentrations of phenylalanine and its metabolites. If untreated, PKU can cause neurological problems such as mental disability and seizures. PKU affects about 1 in 10,000-15,000 people in the United States, and it is estimated that there are about 11,000 adult PKU patients in the United States. Current therapies available for PKU, such as Kuvan® (sapropterin dihydrochloride) require patients to adhere to a restricted diet; Palynziq does not have a dietary requirement. Palynziq reduces blood phenylalanine concentrations by converting phenylalanine to ammonia and trans-cinnamic acid. Due to a high risk of hypersensitivity reactions, Palynziq comes with a REMS program and black box warning. Doses should be administered under the supervision of a health care provider, and epinephrine should be available during treatment.

### Program-Specific Information:

Date Range FFS 4-1-2019 to 3-31-2020				
Drug	Claims	Spend	Cost per unit	Cost per month
PALYNZIQ 2.5 MG/0.5 ML SYR	0	-	\$515.10 MAC	\$15,453.00 to \$30,906.00 MAC
PALYNZIQ 10 MG/0.5 ML SYR	1	\$6,909.87		
PALYNZIQ 20 MG/ML SYR	3	\$44,387.85		

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Palynziq™ (pegvaliase-pqpz)
- Age range: All appropriate MO HealthNet participants aged 18 years or older

SmartPA Clinical Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

## Approval Criteria

### Initial Therapy:

- Documented diagnosis of phenylketonuria (PKU) in the past year **AND**
- Documented adequate therapeutic trial of Kuvan (sapropterin) defined as 180 days of therapy in the past year or ADE/ADRs to Kuvan therapy **AND**
- Documented baseline blood phenylalanine concentrations > 600 micromol/L

### Continuation of Therapy:

- Initial approval of prior authorization in 1 year
- **Renewal of prior authorization may be given following documentation of blood phenylalanine concentrations < 600 micromol/L or at least 20% less than baseline level**

## Denial Criteria

- Therapy will be denied if no approval criteria are met
- **Claim quantity exceeds 2ml per day**

## Required Documentation

Laboratory Results:  
MedWatch Form:

X

Progress Notes:  
Other:

X

## Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)  
Rule Type: CE

## Default Approval Period

1 year

## References

- PALYNZIQ (pegvaliase-pqpz) injection [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; May 2018.
- IPD Analytics. Endocrine and Metabolic Agents: Phenylketonuria. Accessed May 14, 2020.
- Clinical Pharmacology. Pegvaliase: PALYNZIQ. Accessed May 14, 2020.

### *SmartPA Clinical Proposal Form*

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.